Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peripheral versus central airway targeting of inhaled rhDNase in children with cystic fibrosis
NL-OMON23855Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of dornase alfa in cystic fibrosis (CF) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in FEF75 from baseline after 1 month of treatment. Started Sep 2007; status: active, not recruiting.
02
Drugs
dornase alfa
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON23855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23855.